160 | VERLen: TAFASITAMAB, LENALINOMIDE, PLUS RITUXIMAB IN FRONTLINE DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS OVER 80 Y/O OR OLDER, A LYSA PHASE 2 TRIAL
Hematological Oncology · 2025-06 · 43 (S3)
DOI: 10.1002/hon.70093_160 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematological Oncology, online erschienen am 16.06.2025. Verfasst von B. Tessoulin und 22 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Tessoulin, B., Crochet, G., Feugier, P., Fouillet, L., Amorin, S., Abraham, J., Morschhauser, F., Thieblemont, C., Jardin, F., Bernard, S., Schmitt, A., Chauchet, A., Joly, B., Gros, F., Maquet, C., Bailly, S., Pranger, D., Depaus, J., Gutierrez, F. L., …, & Gouill, S. L. (2025). 160 | VERLen: TAFASITAMAB, LENALINOMIDE, PLUS RITUXIMAB IN FRONTLINE DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS OVER 80 Y/O OR OLDER, A LYSA PHASE 2 TRIAL. Hematological Oncology, 43(S3). https://doi.org/10.1002/hon.70093_160
Vancouver
Tessoulin B, Crochet G, Feugier P, Fouillet L, Amorin S, Abraham J, et al. 160 | VERLen: TAFASITAMAB, LENALINOMIDE, PLUS RITUXIMAB IN FRONTLINE DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS OVER 80 Y/O OR OLDER, A LYSA PHASE 2 TRIAL. Hematological Oncology. 2025;43(S3). doi:10.1002/hon.70093_160
BibTeX
@article{Tessoulin2025,
author = {Tessoulin, B. and Crochet, G. and Feugier, P. and Fouillet, L. and Amorin, S. and Abraham, J. and Morschhauser, F. and Thieblemont, C. and Jardin, F. and Bernard, S. and Schmitt, A. and Chauchet, A. and Joly, B. and Gros, F. and Maquet, C. and Bailly, S. and Pranger, D. and Depaus, J. and Gutierrez, F. Llamas and Molina, T. J. and Karfis, I. and Milin, C. and Gouill, S. Le},
title = {160 | VERLen: TAFASITAMAB, LENALINOMIDE, PLUS RITUXIMAB IN FRONTLINE DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS OVER 80 Y/O OR OLDER, A LYSA PHASE 2 TRIAL},
journal = {Hematological Oncology},
year = {2025},
volume = {43},
number = {S3},
doi = {10.1002/hon.70093_160}
}
EUVIMED